316 results about "High fat diet" patented technology

The invention relates to the technical field of microorganisms, and discloses bifidobacterium adolescentis and an application thereof. The collection number of the bifidobacterium adolescentis CCFM8630 is CGMCC No.14395. The bifidobacterium adolescentis CCFM8630 has the advantages that the level of neurotransmitter 5-hydroxytryptamine in peripheral blood of rats can be remarkably upgraded by the bifidobacterium adolescentis CCFM8630; the increased level of hormones such as testosterone in the peripheral blood of the rats due to high-glucose and high-fat diet and anomaly of abundance of Blautiaand Turicibacter in intestinal floras of the rats can be recovered; simulated gastrointestinal fluid can be tolerated, the bifidobacterium adolescentis can be quickly colonized in intestinal tracts,accordingly, rat livers with metabolic syndromes, pathological injury of duodenums and increase of the contents of triglyceride and total cholesterol in serum due to the high-glucose and high-fat dietand oral glucose tolerance can be remarkably improved, and the bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder such as the metabolic syndromes, irritable bowel syndromes and psychological illnesses such as anxiety and depression which are related to the metabolic syndromes.

The invention belongs to the field of animal experiment models, and discloses application of a composite high-fat forage to construct a non-alcoholic fatty liver disease rat model. The high-fat forage is composed of the following raw materials in percent by mass: 77.5% of a rat basic forage, 10% of egg, 10% of coconut oil, 2% of cholesterol, 0.5% of bile salt, and 500mg / kg / d of sodium valproate calculated according to the rat weight. After 8 weeks, rats all have typical non-alcoholic fatty live symptoms, and liver has a lot of fat accumulation along with inflammatory cell infiltration. The model establishing time is short, the success rate is high, and the composite high-fat forage is applicable to pathogenesis research induced by high-fat-diet combined medicines with liver-toxicity side effect, screening of related control measures and efficacy evaluation of treatment medicines.

An animal model of coronary heart disease has been developed where myocardial infarct can be induced by altering the animal's diet. In all embodiments, this animal model is a result of reduced activity of scavenger receptor class BI (SR-BI) and apolipoprotein E (ApoE). In a preferred embodiment, the model is a result of crossbreeding two transgenic mouse lines: a knockout of SR-BI (SR-BI− / −) and an impaired ApoE expressor (hypoE). The impaired ApoE gene results in only 2-5% expression of ApoE and a reduction in cholesterol homeostasis. Resulting animals are predisposed to hypercholesterolemia but can live longer than a year on a normal low fat diet. Serum plasma levels can be significantly elevated by changing the animal's diet to one containing high levels of fat and cholesterol. Within a month on a high fat, high cholesterol diet, animals develop atherosclerosis and myocardial infarction occurs. Survival depends on the nature of the diet and the conditions of animal husbandry and can typically be around 20-30 days after administration of the modified diet depending on the specific conditions. Housing the animals alone or in groups significantly affects survival of these animals on a high fat diet. Analysis of B- and T-cell deficient SR-BI / ApoE / RAG2 triple knockout mice established that B- and T-lymphocytes do not play a key role in the pathophysiology of the SR-BI ApoE dKO model of human disease. These animal models can be used to study mechanisms and progression of CHD as a function of diet, treatment with drugs to be screened for efficacy or undesirable side effects, and social environmental effects.

The invention discloses lactobacillus plantarum with functions of losing weight and reducing lipid and an application thereof, and belongs to the technical field of microorganisms; the lactobacillus plantarum LP-KFY04 is lactic acid bacteria (LAB), and the preservation number is CGMCC No. 15651; lactobacillus plantarum KFY04 is separated from yoghourt and is used for mice maintaining 45% fat diet;then liver and serum samples are obtained, and gene expression related to the TG level, oxidation, inflammation and PPAR pathway is detected to evaluate the influence of LP-KFY04 on obesity, oxidation and inflammation; and results show that the LP-KFY04 can be used for relieving obesity of mice induced by high fat diet, and the LP-KFY04 can effectively reduce liver injury and fat accumulation caused by obesity.

The invention provides a lactobacillus plantarum BUFX (Lactobacillus plantarum) and application thereof in metabolic syndrome, which relate to the technical field of microorganisms and application of the microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.22172. The lactobacillus plantarum is separated and screened from feces of adults, can promote glucose consumption of HepG2 hepatoma carcinoma cells, inhibits alpha-amylase activity, can remarkably reduce the weight and blood fat content of high-fat diet mice, improves glucose tolerance, and has important application significance for preventing or treating metabolic diseases such as diabetes, obesity and the like.

Disclosed are a composition for preventing or treating diabetes, diabesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

The invention discloses application of ampelopsin in preparing medicines for treating obesity, and relates to preparation and application of flavonoids compounds. The ampelopsin is used for preparing medicines or health products for treating the obesity, including oral tablets, capsules, granules, oral solution, sustained-release agents, pills and injection solution for treating the obesity, and pharmaceutically acceptable conventional formulations. The ampelopsin has obvious weight-losing effect on obese mice and overweight mice induced by high-fat diet; after the ampelopsin is poured into stomachs of the obese mice in a dose of 25.0mg / kg for 2 weeks, the abdominal fat is obviously reduced, shoulder fat cells are obviously shrunk, the weight is reduced to be normal, and the mice are generally good in conditions, freely acts and have smooth hairs. The maximum tolerance does of the mice through stomach perfusion can reach 18g / kg.

The present invention provides methods and compositions for preventing hyperinsulinemia that can result from therapeutic administration of growth hormone. The methods are carried out by imposing a restricted high-fat diet and / or by administering one or more drugs that lower serum lipids.

The invention discloses bifidobacterium pseudocatenulatum CCFM1047, a composition, fermented food, application and bacterial agent of the bifidobacterium pseudocatenulatum CCFM1047 and a preparation method of the bacterial agent of the bifidobacterium pseudocatenulatum CCFM1047. The bifidobacterium pseudocatenulatum CCFM1047 can tolerate the gastrointestinal environment of the human body, significantly improve abnormal fasting blood glucose and abnormal oral glucose tolerance of a mouse with the metabolic syndrome, reduce the area under the drug-time curve of glucose tolerance, reduce the serum insulin level, significantly relieve the weight rise of the mouse, significantly relieve the rise, caused by the high fat diet, of content of low density lipoprotein cholesterol in serum and triglyceride in the liver of the mouse with the metabolic syndrome and significantly relieve the rise, caused by the high fat diet, of Proteus in the intestinal tract; the bifidobacterium pseudocatenulatum CCFM1047 is used for preparing the medicine composition and the fermented food which relieve the metabolic syndrome and reduce the occurrence of diseases such as the Parkinson disease, intestinal infection and urinary tract and kidney infection and has a quite wide application prospect.